Learn More
PURPOSE To evaluate the association of latanoprost with anterior chamber uveitis in glaucoma patients. METHODS We retrospectively reviewed 527 charts in latanoprost treated patients with: no prior uveitis (Group 1); prior uveitis but were inactive at the time of the study (Group 2); and active uveitis (Group 3). RESULTS In Group 1 five (1.0%) of 505(More)
BACKGROUND AND OBJECTIVE The presentation and initial response to treatment of consecutive patients with exfoliation glaucoma (PXE) and primary open-angle glaucoma (POAG) were evaluated prospectively. PATIENTS AND METHODS Forty-six consecutive newly diagnosed patients with POAG and PXE were included in a prospective study that evaluated the initial(More)
PURPOSE To determine whether high-density lipoprotein and total cholesterol levels were risk factors for increased intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. METHODS We measured total cholesterol, high-density lipoprotein, and total cholesterol/high-density lipoprotein ratio in 25 patients with open-angle(More)
This study was undertaken to evaluate the safety and efficacy of switching patients treated with timolol maleate to timolol hemihydrate. In patients with ocular hypertension or chronic open-angle glaucoma treated with beta-blockers for at least three months, we prescribed timolol maleate solution 0.5% given twice daily for one month. We then switched each(More)
PURPOSE To evaluate the use of latanoprost 0.005% given once daily to simplify a patient's glaucoma medical regimen. METHODS We reviewed 527 charts of which we included 61 patients (61 eyes) with either ocular hypertension or primary open-angle glaucoma who were prescribed latanoprost for the purpose of simplifying their glaucoma medical regimen. The(More)
OBJECTIVE To evaluate the daily cost of beta-blocker therapy among commercially available products. METHODS Ten different beta-adrenergic blocker preparations, each in 10-mL bottles (except Timoptic-XE [Merck brand of timolol maleate gel-forming solution], which was in a 5-mL bottle), were acquired from a local pharmacy. Each of 10 subjects dispensed 10(More)
PURPOSE We studied patients with chronic open-angle glaucoma who had similar intraocular pressures to determine whether surgical or medical therapy is more effective in preventing progressive, long-term, glaucomatous damage. METHODS Included in this study were patients with chronic open-angle glaucoma who were followed for 3 years or longer and were(More)
BACKGROUND AND OBJECTIVE To determine the results of phacoemulsification and combined trabeculectomy in subjects receiving either a 3- or a 6-mm scleral incision. PATIENTS AND METHODS The authors evaluated consecutive patients who underwent combined phacoemulsification and trabeculectomy with a 3-mm incision. These patients were individually matched by(More)
The purpose of this study was to evaluate the drop characteristics of newer glaucoma medicines compared to timolol solution and timolol gel forming solution (Timoptic-XE, Merck). We evaluated latanoprost 0.005% (2.5 ml bottle), brimonidine 0.2%, apraclonidine 0.5%, dorzolamide 2%, timolol solution 0.5% (5 and 10 ml bottles), and timolol gel forming solution(More)
The purpose of this study was to evaluate differences in efficacy and safety of latanoprost as monotherapy compared to adjunctive therapy in primary open-angle glaucoma. We reviewed records of 527 patients who were treated with latanoprost as mono- or adjunctive therapy to reduce the intraocular pressure. Each patient was treated at least three months(More)